Chronic Kidney Disease, Healthy, Myocardial Fibrosis
Conditions
Keywords
Healthy, Myocardial fibrosis, Chronic kidney disease
Brief summary
This study is a feasibility study to validate magnetizatin transfer (MT)-weighted balanced steady state free precession (bSSFP) cine cardiac magnetic resonance (CMR) against current clinical gold standard diagnostics, and to determine the applicability of MT-weighted bSSFP cine CMR for diagnosis of fibrotic remodeling in chronic kidney disease (CKD5) patients. Participants will not receive a study drug or placebo and will not be randomized. A total of 250 participants will be enrolled into this study.
Detailed description
This study had two treatment arms. Arm 1: Participants will be enrolled in this arm if they have been referred to the Gill Heart Institute MRI center for diagnostic late gadolinium enhancement (LGE) -CMR imaging of fibrosis, or if they are a healthy volunteer. If a participant is a Gill Heart Institute referral patient , they will receive an intravenous (through a vein in the arm) infusion of gadolinium as part of their clinical examination. Participants will also have electrocardiogram (ECG) waveform performed in order to gate the MRI scan. The MRI scan of the heart, for which the participant has been referred will last approximately 1 hour. Participants will have an additional 5-10 minutes of scans performed, none of which require additional infusions. If the participant is a healthy volunteer, they will have an ECG waveform performed in order to gate your MRI scan, and they will have approximately 30-45 minutes of scanning performed on their heart. Participants will not receive an infusion of gadolinium. Arm 2: Only participants who are already participating in a study being conducted by Dr. Harmut Malluche at the University of Kentucky, Department of Nephrology or, if you are a healthy volunteer, will be enrolled into this arm. In this arm participants will receive an MRI of their heart, lasting 30-45 minutes. Participants will not receive an infusion of gadolinium.
Interventions
DRUGArm 1 MRI with gadolinium
Healthy volunteers will not receive gadolinium
Sponsors
Moriel Vandsburger
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
Arm 1 Inclusion Criteria: * Participants between the ages of 20 and 80 * Diagnosis or suspicion of myocardial fibrosis * Referral for LGE-CMR
Exclusion criteria
* Confirmed acute MI within the prior 72 hours * Unstable ECG or arrhythmia as determined by the referring physician * Inability to hold one's breath for at least 10 seconds * Standard MRI safety
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Arm 1 - Validation of gadolinium free fibrosis imaging against current standard of care LGE-CMR | 36 months | Results from this arm will focus on validating cine FI measured from MT-weighted bSSFP cine CMR against LGE-CMR and MOLLI characterization of fibrosis in patients referred to the Gill Heart Institute. |
| Arm 2 - Imaging of myocardial fibrosis in CKD patients | 48 months | Will test the hypothesis that MT-weighted CMR can be applied to identify fibrotic remodeling in the hearts of CKD5 patients |
Countries
United States
Outcome results
None listed